Literature DB >> 16432373

Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.

Konstantinos Karmiris1, Ioannis E Koutroubakis, Costas Xidakis, Maria Polychronaki, Theodora Voudouri, Elias A Kouroumalis.   

Abstract

BACKGROUND: There is evidence that adipocytokines play an important role in metabolism and in inflammation. Because human metabolism dramatically changes in inflammatory bowel disease (IBD) and chronic inflammation is the hallmark of the disease, we studied serum levels of leptin, adiponectin, resistin, and ghrelin in patients with ulcerative colitis (UC) and Crohn's disease (CD) in comparison with healthy controls (HC).
METHODS: Leptin, adiponectin, resistin, and active ghrelin serum levels were measured in 100 IBD patients (46 UC and 54 CD) and in 60 matched HC using commercially available enzyme-linked immunosorbent assays. Leptin, adiponectin, resistin, and ghrelin levels were correlated with disease activity, type, localization, and treatment.
RESULTS: Mean serum leptin levels were 10.6+/-2.0 ng/mL in UC patients, 12.5+/-2.6 ng/mL in CD patients, and 15.0+/-1.8 ng/mL in HC (P=.01). Mean serum adiponectin levels were 9514.8+/-787.8 ng/mL in UC patients, 7651.1+/-613 ng/mL in CD patients, and 7270.6+/-559.4 ng/mL in HC (P=.05). Mean serum resistin levels were 21.2+/-2.2 ng/mL in UC patients, 18.7+/-1.6 ng/mL in CD patients and 11.8+/-0.6 ng/mL in HC (P=.0002). Mean serum ghrelin levels were 48.2+/-4.2 pg/mL in UC patients, 49.4+/-4.6 pg/mL in CD patients and 14.8+/-3.0 pg/mL in HC (P<.0001). Serum levels of these adipocytokines were not correlated with either C-reactive protein levels or the clinical indices of activity. No association between serum adipocytokines levels and disease localization in both UC and CD patients was found. Only serum ghrelin was significantly higher in ileal compared with colonic CD (P=.04).
CONCLUSIONS: Serum levels of adiponectin, resistin, and active ghrelin are increased whereas serum levels of leptin are decreased in patients with IBD. Further studies are needed to elucidate the role of adipocytokines in IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432373     DOI: 10.1097/01.MIB.0000200345.38837.46

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  101 in total

1.  The effect of body weight on the severity and clinical course of ulcerative colitis.

Authors:  Denia Stabroth-Akil; Ludger Leifeld; Roland Pfützer; Julia Morgenstern; Wolfgang Kruis
Journal:  Int J Colorectal Dis       Date:  2014-11-14       Impact factor: 2.571

Review 2.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  Impact of Obesity on the Management of Inflammatory Bowel Disease.

Authors:  Amanda M Johnson; Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-07

Review 4.  Adipose tissue and inflammatory bowel disease pathogenesis.

Authors:  Christopher Fink; Iordanes Karagiannides; Kyriaki Bakirtzi; Charalabos Pothoulakis
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

5.  Does plasma resistin level have a role in predicting inflammatory bowel disease activity?

Authors:  N A Abdel Kader; F A Ali El-Din; E A A Khatab; N E ELAbd
Journal:  Indian J Gastroenterol       Date:  2010-06

Review 6.  Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways.

Authors:  Dennis D Taub; William J Murphy; Dan L Longo
Journal:  Curr Opin Pharmacol       Date:  2010-06-04       Impact factor: 5.547

7.  Outcomes of Bariatric Surgery in Patients with Inflammatory Bowel Disease.

Authors:  Ali Aminian; Amin Andalib; Maria R Ver; Ricard Corcelles; Philip R Schauer; Stacy A Brethauer
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

8.  Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.

Authors:  Jennifer Kaplan; Marchele Nowell; Ranjit Chima; Basilia Zingarelli
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

9.  Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.

Authors:  L Sieminska; D Niedziolka; A Pillich; B Kos-Kudla; B Marek; M Nowak; H Borgiel-Marek
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

10.  Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.

Authors:  Martin H Holtmann; Frank Krummenauer; Christina Claas; Kristina Kremeyer; Dirk Lorenz; Olivia Rainer; Iris Vogel; Ulrich Böcker; Stephan Böhm; Carsten Büning; Rainer Duchmann; Guido Gerken; Hans Herfarth; Norbert Lügering; Wolfgang Kruis; Max Reinshagen; Jan Schmidt; Andreas Stallmach; Jürgen Stein; Andreas Sturm; Peter R Galle; Daan W Hommes; Geert D'Haens; Paul Rutgeerts; Markus F Neurath
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.